Bharat Biotech signs deal to send 20 mn Covaxin doses to Brazil

Shipments to be made during second and third quarters of current calendar

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
In January, Bharat Biotech had indicated that it has signed an agreement with Precisa Medicamentos, a wholesaler of drugs in Brazil to supply Covaxin to that country.
Sohini Das Mumbai
1 min read Last Updated : Feb 26 2021 | 11:33 PM IST
Hyderabad-based vaccine maker Bharat Biotech said it has signed an agreement to supply 20 million doses of its Covid-19 shot Covaxin to Brazil during the second and third quarters of 2021. 

The firm said there is 'strong interest' in Covaxin and it is committed to supplying promptly. This is significant in the backdrop of the mutant strain identified in Brazil. 

In January, Bharat Biotech had indicated that it has signed an agreement with Precisa Medicamentos, a wholesaler of drugs in Brazil to supply Covaxin to that country. 

A team from Precisa Medicamentos met Bharat Biotech chairman and managing director Krishna Ella and discussed the export possibilities of Covaxin. "In principle, it is understood that supplies of Covaxin to be prioritised for the public market, through a direct procurement by the Government of Brazil. Supplies to the private market would be based upon receipt of market authorization from ANVISA, the Brazilian regulatory authority," Bharat Biotech had said in a statement. 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBharat BiotechCoronavirus VaccineBrazil

Next Story